Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph I/IIa Escalation/Expansion FIH, Open, Multi Center, Single Arm Study Evaluating Safety, Dosimetry and Early Efficacy of 177Lu-SN201 in Progressive/Treatment-refractory, Locally Advanced, Unresectable Metastatic or Recurrent Solid Tumors

NCT06184035 is registered in ClinicalTrials.gov with Spago Nanomedical AB as lead sponsor.

NCT NCT06184035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06184035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph I/IIa Escalation/Expansion FIH, Open, Multi Center, Single Arm Study Evaluating Safety, Dosimetry and Early Efficacy of 177Lu-SN201 in Progressive/Treatment-refractory, Locally Advanced, Unresectable Metastatic or Recurrent Solid Tumors
Lead sponsor
Spago Nanomedical AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 6, 2023
Completion date
December 31, 2027
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic cancer, recurrent solid tumor, refractory cancer, solid tumor, unresectable solid tumor